CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 128 enrolled
Drug / intervention
Enteric-coated mycophenolate sodium (EC-MPS)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00369278
NCT00369278Phase 3Completed

Multi-center, Open-label, Prospective, Randomized, Parallel Group Study Investigating an Intensified Enteric-coated Mycophenolate Sodium (EC-MPS) Dosing Regimen in Comparison to a Standard Dosing Regimen of EC-MPS in Combination With Cyclosporin Microemulsion and Corticosteroids in de Novo Renal Transplant Patients

Novartis Pharmaceuticals·interventional·Posted Aug 29, 2006·Updated Mar 29, 2011

In Brief

A Phase 3 clinical trial evaluating Enteric-coated mycophenolate sodium (EC-MPS) for Renal Transplantation. Completed, enrolled 128 participants across 1 site.

Detailed Summary

This study will assess the association of an initially intensified dosing regimen of enteric-coated mycophenolate sodium (EC-MPS) during the first 6 weeks post renal transplantation with acute rejections relative to the rapid achievement of an MPA (mycophenolic acid) exposure of ≥ 40 mg\*h/L compared to a standard dosing regimen of EC-MPS. Additionally, this study will assess safety and tolerability of the intensified dosing regimen of EC-MPS. This study will be conducted in 2 stages (Stage I and Stage II).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesGermany
Collaborators--

Timeline

Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 29, 2006
Enrollment StartJun 1, 2006
Primary CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 19.8 years ago

Interventions

Enteric-coated mycophenolate sodium (EC-MPS)drug

Tablets for oral administration